BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770. [PMID: 33864798 DOI: 10.1016/j.metabol.2021.154770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Radbakhsh S, Katsiki N, Santos RD, Mikhailidis DP, Mantzoros CS, Sahebkar A. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism 2022;:155211. [PMID: 35533891 DOI: 10.1016/j.metabol.2022.155211] [Reference Citation Analysis]
2 Balta S. Atherosclerosis and Non-Alcoholic Fatty Liver Disease. Angiology 2022;:33197221091317. [PMID: 35476909 DOI: 10.1177/00033197221091317] [Reference Citation Analysis]
3 Park J, Kim G, Kim H, Lee J, Lee YB, Jin SM, Hur KY, Kim JH. The association of hepatic steatosis and fibrosis with heart failure and mortality. Cardiovasc Diabetol 2021;20:197. [PMID: 34583706 DOI: 10.1186/s12933-021-01374-8] [Reference Citation Analysis]
4 van den Hoek AM, de Jong JCBC, Worms N, van Nieuwkoop A, Voskuilen M, Menke AL, Lek S, Caspers MPM, Verschuren L, Kleemann R. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. Metabolism 2021;124:154873. [PMID: 34478753 DOI: 10.1016/j.metabol.2021.154873] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sahin S, Karadeniz A. Pancretic Fat Accummulation is Associated with Subclinical Atherosclerosis. Angiology 2021;:33197211038334. [PMID: 34607492 DOI: 10.1177/00033197211038334] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Filippatos TD. Non-Alcoholic Fatty Pancreas Disease: A Diagnosis of Increasing Importance. Angiology 2021;:33197211053902. [PMID: 34747669 DOI: 10.1177/00033197211053902] [Reference Citation Analysis]
7 Chung GE, Chang Y, Cho Y, Cho EJ, Yoo JJ, Park SH, Han K, Shin DW, Yu SJ, Kim YJ, Yoon JH. The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis. Biomedicines 2021;9:1948. [PMID: 34944764 DOI: 10.3390/biomedicines9121948] [Reference Citation Analysis]
8 Park J, Kim G, Kim B, Han K, Kwon SY, Park SH, Lee Y, Jin S, Kim JH. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01483-y] [Reference Citation Analysis]
9 Yardeni D, Toledano R, Novack V, Shalev A, Wolak A, Rotman Y, Etzion O. The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity. J Cardiovasc Pharmacol Ther 2022;27:107424842210745. [DOI: 10.1177/10742484221074585] [Reference Citation Analysis]
10 Ryter SW. Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders. Antioxidants 2022;11:555. [DOI: 10.3390/antiox11030555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Athyros VG, Katsiki N, Mikhailidis DP. Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021 Oct 1:101816. doi: 10.1016/j.clinre.2021.101816. Epub ahead of print. PMID:34607067. Clin Res Hepatol Gastroenterol 2021;:101842. [PMID: 34920141 DOI: 10.1016/j.clinre.2021.101842] [Reference Citation Analysis]